


The Biochemical Basis of Neuropharmacology

SIXTH
EDITION



Jack R. Cooper Floyd E. Bloom
Robert H. Roth

The Biochemical Basis of Neuropharmacology

SIXTH EDITION

JACK R. COOPER, Ph.D.

Professor of Pharmacology
Yale University School of Medicine

FLOYD E. BLOOM, M.D.

Chairman, Department of Neuropharmacology
The Scripps Research Institute
La Jolla, California

ROBERT H. ROTH, Ph.D.

Professor of Pharmacology and Psychiatry
Yale University School of Medicine

New York Oxford
OXFORD UNIVERSITY PRESS
1991

Oxford University Press

Oxford New York Toronto
Delhi Bombay Calcutta Madras Karachi
Petaling Jaya Singapore Hong Kong Tokyo
Nairobi Dar es Salaam Cape Town
Melbourne Auckland

and associated companies in
Berlin Ibadan

Copyright © 1970, 1974, 1978, 1982, 1986, 1991
by Oxford University Press, Inc.

Published by Oxford University Press, Inc.,
200 Madison Avenue, New York, New York 10016

Oxford is a registered trademark of Oxford University Press

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of Oxford University Press.

Library of Congress Cataloging-in-Publication Data

Cooper, Jack R., 1924—

The biochemical basis of neuropharmacology / Jack R. Cooper,
Floyd E. Bloom, Robert H. Roth.—6th ed.

p. cm. Includes bibliographical references and index.

ISBN 0-19-507117-4 ISBN 0-19-507118-2 (pbk.)

I. Neurochemistry. 2. Neuropharmacology. I. Bloom, Floyd E.
II. Roth, Robert H., 1939— . III. Title.

[DNLM: 1. Nerve Tissue—chemistry. 2. Nerve Tissue—physiology.

3. Nervous System—drug effects. 4. Neuropharmacology.

5. Neuroregulators—physiology. QV 77 C777b]

QP356.3.C66 1991 615'.78—dc20 DNLM/DLC

for Library of Congress 91-1951

9 8 7 6 5 4

Printed in the United States of America
of acid-free paper

Preface to the Sixth Edition

We must confess that it is with some amazement that we find ourselves doing a sixth edition of this little book: neither we nor Jeffrey House, our editor, expected it to be that popular. With this edition we have reinstated the chapter on memory and learning, since experimentation in this field has achieved much more credibility in the past several years. The other major change is a reorganization of the chapters on the catecholamines. All other chapters have been updated, particularly with reference to the explosion of new information on peptides, receptor subtypes, and G proteins.

Despite some complaints from colleagues whose contributions we fail to cite, we still maintain our position of mainly citing recent reviews that contain useful references, rather than citing the original papers.

June 1991

J.R.C.
F.E.B.
R.H.R.

Contents

- 1 | Introduction, 3

- 2 | Cellular Foundations of Neuropharmacology, 9
 - CYTOLOGY OF THE NERVE CELL, 9
 - BIOELECTRIC PROPERTIES OF THE NERVE CELL, 15
 - ANALYSIS OF MEMBRANE ACTIONS OF DRUGS AND TRANSMITTERS IN VITRO, 34
 - APPROACHES, 38
 - IDENTIFICATION OF SYNAPTIC TRANSMITTERS, 39
 - THE STEPS OF SYNAPTIC TRANSMISSION, 44

- 3 | Molecular Foundations of Neuropharmacology, 48
 - FUNDAMENTAL MOLECULAR INTERACTIONS, 53
 - MOLECULAR STRATEGIES IN NEUROPHARMACOLOGY, 62
 - GENERAL STRATEGIES FOR CLONE SCREENING AND SELECTION, 63
 - BEYOND THE CLONES, 68

- 4 | Metabolism in the Central Nervous System, 75

- 5 | Receptors, 88
 - CLASSIFICATION, 89
 - DEFINITION, 94
 - ASSAYS, 94
 - IDENTIFICATION, 96
 - KINETICS AND THEORIES OF DRUG ACTION, 98

- 6 | Modulation of Synaptic Transmission, 111
 - DEFINITIONS, 111
 - SECOND MESSENGERS, 114

x | Contents

7 | Amino Acid Transmitters, 133

GABA, 133

DISTRIBUTION, 134

METABOLISM, 135

GABA RECEPTORS, 143

PHARMACOLOGY OF GABAERGIC NEURONS, 151

GLYCINE, 166

GLUTAMIC ACID, 172

EXCITATORY AMINO ACID RECEPTORS, 179

8 | Acetylcholine, 190

ASSAY PROCEDURES, 190

SYNTHESIS, 191

CHOLINE TRANSPORT, 193

CHOLINE ACETYLTRANSFERASE, 195

ACETYLCHOLINESTERASE, 196

UPTAKE, SYNTHESIS, AND RELEASE OF ACH, 201

CHOLINERGIC PATHWAYS, 205

CHOLINERGIC RECEPTORS, 207

ACH IN DISEASE STATES, 213

9 | Norepinephrine and Epinephrine, 220

MORPHOLOGY OF ADRENERGIC NEURON, 221

LIFE CYCLE OF THE CATECHOLAMINES, 224

PHARMACOLOGY OF NORADRENERGIC NEURONS, 255

CNS CATECHOLAMINE NEURONS, 258

SYSTEMS OF CATECHOLAMINE PATHWAYS IN THE CNS, 261

LOCUS CERULEUS, 261

THE LATERAL TEGMENTAL NORADRENERGIC NEURONS, 264

EPINEPHRINE NEURONS, 264

BIOCHEMICAL ORGANIZATION, 269

PHARMACOLOGY OF CENTRAL CATECHOLAMINE-CONTAINING NEURONS, 271

CATECHOLAMINE THEORY OF AFFECTIVE DISORDER, 278

10 | Dopamine, 285

DOPAMINERGIC SYSTEMS, 285

BIOCHEMICAL ORGANIZATION, 295

POSTSYNAPTIC DOPAMINE RECEPTORS, 300

PHARMACOLOGY OF DOPAMINERGIC SYSTEMS, 313

- SPECIFIC DRUG CLASSES, 320
 PARKINSON'S DISEASE, 328
 DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA, 332
- 11 | Serotonin (5-hydroxytryptamine) and Histamine, 338
 SEROTONIN, 338
 BIOSYNTHESIS AND METABOLISM OF SEROTONIN, 339
 PINEAL BODY, 346
 LOCALIZING BRAIN SEROTONIN TO NERVE CELLS, 347
 CELLULAR EFFECTS OF 5-HT, 351
 5-HT RECEPTORS, 354
 HISTAMINE, 367
 HISTAMINE SYNTHESIS AND CATABOLISM, 369
 HISTAMINE-CONTAINING CELLS, 371
 HISTAMINE RECEPTORS, 374
- 12 | Neuroactive Peptides, 381
 SOME BASIC QUESTIONS, 382
 THE GRAND PEPTIDE FAMILIES, 392
 CHEMICAL AND CELLULAR RELATIONSHIPS AMONG THE OPIOID PEPTIDES, 404
 INDIVIDUAL PEPTIDES WORTH TRACKING, 409
 A READER'S GUIDE TO PEPTIDE POACHING, 419
- 13 | Cellular Mechanisms in Learning and Memory, 428
 CELLULAR MODELS OF LEARNING IN INVERTEBRATE NERVOUS SYSTEMS, 431
 THE RABBIT NICTITATING MEMBRANE REFLEX AND ASSOCIATIVE LEARNING, 434
 LONG-TERM POTENTIATION: A VERTEBRATE MODEL OF SYNAPTIC PLASTICITY, 437
 ARE THERE ANY NATURAL MEMORY DRUGS?, 441
 APPROACHING THE NEUROPHARMACOLOGY OF HUMAN MEMORY, 443

I | Introduction

Neuropharmacology can be defined simply as the study of drugs that affect nervous tissue. This, however, is not a practical definition since a great many drugs whose therapeutic value is extraneural can affect the nervous system. For example, the cardiotonic drug digitalis will not uncommonly produce central nervous system effects ranging from blurred vision to disorientation. For our purposes we must accordingly limit the scope of neuropharmacology to those drugs specifically employed to affect the nervous system. The domain of neuropharmacology would thus include psychotropic drugs that affect mood and behavior, anesthetics, sedatives, hypnotics, narcotics, anticonvulsants, analeptics, analgetics, and a variety of drugs that affect the autonomic nervous system.

Since, with few exceptions, the precise molecular mechanism of action of these drugs is unknown, and since recitations of their absorption, metabolism, therapeutic indications, and toxic liability can be found in most textbooks of pharmacology, we have chosen to take a different approach to the subject. We will concentrate on the biochemistry and physiology of nervous tissue, emphasizing neurotransmitters, and will introduce the neuropharmacologic agents where their action is related to the subject under discussion. Thus, a discussion of LSD is included in the chapter on serotonin, and a suggested mechanism of action of the antipsychotic drugs is found in Chapter 10.

It is not difficult to justify this focus on either real or proposed neurotransmitters since the drugs act at junctions rather than on the events that occur with axonal conduction or within the cell body. Except for local anesthetics, which interact with axonal membranes, all neuropharmacological agents whose mechanisms of action are to some extent documented seem to be involved primarily with synaptic events. This finding appears quite logical in view of the regulatory mechanisms in the transmission of nerve impulses. The extent to

which a neuron is depolarized or hyperpolarized will depend largely on its excitatory and inhibitory synaptic inputs, and these inputs must obviously involve neurotransmitters, neuromodulators, or neurohormones. What is enormously difficult to comprehend is the contrast between the action of a drug on a simple neuron, which causes it either to fire or not to fire, and the wide diversity of central nervous system effects, including subtle changes in mood and behavior which that same drug will induce. As will become clearer in subsequent chapters, at the molecular level, an explanation of the action of a drug is often possible; at the cellular level, an explanation is sometimes possible; but at a behavioral level, our ignorance is abysmal. There is no reason to assume, for example, that a drug that inhibits the firing of a particular neuron will therefore produce a depressive state in an animal: there may be dozens of unknown intermediary reactions involving transmitters and modulators between the demonstration of the action of a drug on a neuronal system and the ultimate effect on behavior.

However, the fact that one can find compounds with a specific chemical structure to control a given pathological condition is an exciting experimental finding, since it suggests an approach that the neuropharmacologist can use to clarify normal as well as abnormal brain chemistry and physiology. For instance, the use of drugs that affect the adrenergic nervous system has uncovered basic and hitherto unknown neural properties such as the uptake, storage, and release of the biogenic amines. The recognition of the analogy between curare poisoning in animals and myasthenia gravis in humans led to the understanding of the cholinergic neuromuscular transmission problem in myasthenia gravis and to subsequent treatment with anticholinesterases.

We have already referred to neuroactive agents involved in synaptic transmission as neurotransmitters, neuromodulators, and neurohormones, so definitions are now in order. Although we can define these terms in a strict, rigid fashion, it will be apparent—as noted later—that it is an exercise in futility to apply these definitions to a neuroactive agent as a classification unless one both understands

its activity and specifies its locus. Briefly, the traditional definition of a *neurotransmitter* states that the compound must be synthesized and released presynaptically; it must mimic the action of the endogenous compound that is released on nerve stimulation; and, where possible, a pharmacological identity is required where drugs that either potentiate or block postsynaptic responses to the endogenously released agent also act identically to the administered suspected neurotransmitter. Conventionally, based on the studies of ACh at the neuromuscular junction, transmitter action was thought to be a brief and highly restricted point-to-point process. If one takes the word *modulation* literally, then a *neuromodulator* has no intrinsic activity but is only active in the face of ongoing synaptic activity where it can modulate transmission either pre- or postsynaptically. In many instances, however, a modulating agent does produce changes in conductance or membrane potential. Typically, modulatory effects involve a second messenger system. A *neurohormone* can be released from both neuronal and nonneuronal cells and—most important to the definition travels—in some circulation to act at a site distant from its release site. Just how far a neurohormone has to travel before it loses its neurotransmitter status and becomes a neurohormone has never been decided.

We stated earlier that while we could define these terms, it would be of little use to pigeonhole known neuroactive compounds until the site of action and the activity of the agent was specified. For example, dopamine is a certified neurotransmitter in the striatum, yet it is released from the hypothalamus and travels through the hypophyseal-portal circulation to the pituitary where it inhibits the release of prolactin. Here it obviously fits the definition of a neurohormone. Similarly, serotonin is a neurotransmitter in the raphe nuclei, yet at the facial motor nucleus it acts primarily as a neuromodulator and secondarily as a transmitter. Most peptides with their multiple activities in the brain and gut are generally considered to be neuromodulators, yet Substance P fulfills the criteria of a transmitter at sensory afferents to the dorsal horn of the spinal cord. In sum, the plethora of exceptions to the aforementioned definitions of

transmitter, modulator, and hormone has generated confusion in the literature. Better to describe the activity of a neuroactive agent at a specified site rather than attempt to give a profitless definition.

The multidisciplinary aspects of pharmacology in general are particularly relevant in the field of neuropharmacology, where a “pure” neurophysiologist or neurochemist would be severely handicapped in elucidating drug action at a molecular level. The neuropharmacologist should be aware of the tools that are available for the total dissection of a biological problem. These would include morphological techniques such as electron microscopy, fluorescence microscopy, and freeze-etching, and immunological techniques as a basis for developing radioimmunoassays, immunocytochemistry, and monoclonal antibodies, as well as the classical electrophysiological and biochemical procedures. In addition, if the investigator is concerned with the action of psychotropic drugs, a prerequisite is some knowledge of the techniques and pitfalls of behavioral testing.

In science one measures something. One must know what to measure, where to measure it, and how to measure it. This sounds rather obvious, but the student should be aware that, particularly in the neural sciences, these seemingly simple tasks can be enormously difficult. For example, suppose one were interested in elucidating the presumed biochemical aberration in schizophrenia. *What* would one measure? ATP? Glucose? Ascorbic acid? Unfortunately, this problem early on had been zealously investigated by people who measured everything they could think of, generally in the blood, in their search for differences between normal individuals and schizophrenics. As could be predicted, the problem was not solved. (It may be assumed, however, that these studies produced a large population of anemic schizophrenics because of all the bloodletting.) In recent times it has been demonstrated that antidepressant drugs inhibit norepinephrine reuptake (see Chapter 9). Although this biochemical reaction takes place immediately in test tubes containing brain tissue, patients who are given antidepressant medication do now show beneficial effects for about 2 weeks. The inference, therefore, is that the drug itself and its biochemical reaction do not produce the ameliorative effect, rather it is the adaptation of the brain

to the presence of the drug that is beneficial. The question then is what is this adaptation; the answer is we still don't know what to measure.

Deciding *where* to measure something in neuroscience is complicated by the heterogeneity of nervous tissue: In general, unless one has a particular axon to grind, it is preferable to use peripheral nerve rather than the CNS. Suburban neurochemists have an easier time than their CNS counterparts, since it is not only a question of which region of the brain to use for the test preparation but which of the multitude of cell types within each area to choose. If a project involved a study of amino-acid transport in nervous tissue, for example, would one use isolated nerve-ending particles (synaptosomes), glial cells, neuronal cell bodies in culture, a myelinated axon, or a ganglion cell? Up to the present time most investigators have used cortical brain slices, but the obvious disadvantage of this preparation is that one has no idea which cellular organelle takes up the amino acid.

How to measure something is a surprisingly easy question to answer, at least if one is dealing with simple molecules. With the recent advances in microseparation techniques and in fluorometric, radiometric, and immunological assays, there is virtually nothing that cannot be measured with a high degree of specificity and sensitivity. In this regard one should be careful not to overlook the classical bioassay, which tends to be scorned by young investigators but is in fact largely responsible for striking progress in our knowledge of both the prostaglandins and the opiate receptor with its peptide agonists. The major problem is with macromolecules. How can neuronal membranes be quantified, for example, if extraneuronal constituents are an invariable contaminant and if markers to identify unequivocally a cellular constituent are often lacking? The quantitative and spatial measurement of receptors utilizing autoradiography is also a key problem (see Chapter 5).

This harangue about measurement is meant to point out that what would on the surface appear to be the simplest part of research can in fact be very difficult. It is vital that students learn not to accept data without a critical appraisal of the procedures that were employed to obtain the results.

Finally, although the theme is not explicitly dealt with in this book, students may find it educational and often entertaining to attempt to define patterns of research design in neuropharmacology as well as current trends in research areas. One common pattern is for someone to observe something in brain tissue, trace its regional distribution in the brain, and then perform a developmental study of the phenomenon in laboratory animals from prenatal through adult life. Another common pattern is for someone to develop a technique and then search (sometimes with what appears to be desperation) for projects that will utilize the technique. Yet another somewhat simplistic idea is that of attempting to relate a behavioral effect to a changing level of a single neurotransmitter, invariably the one that a team has just learned how to measure. Current trends in the neural sciences that are related to neuropharmacology include isolating ion channels, utilizing molecular genetics to uncover new peptides, neural cartography (the mapping of transmitters and neuroactive peptides in the CNS), searching for toxins with specific effects on conduction or transmission, cloning and characterizing receptors for drugs as well as endogenous neuroactive agents, and identifying trophic factors involved in synaptogenesis and neuronal regulation. It can also easily be predicted that within the next few years an intensive search will be undertaken to explain the function and integration of the approximately three dozen "classical" neurotransmitters, the neuroactive peptides, and the unclassifiable items such as adenosine in eliciting behavioral changes. Clearly, neuropharmacologic agents will be invaluable probes in this search.

2 | Cellular Foundations of Neuropharmacology

As we begin to consider the particular problems that underlie the analysis of drug actions in the central nervous system, it may be asked, “Just what is so special about nervous tissue?” Nerve cells have two special properties that distinguish them from all other cells in the body. First, they can conduct bioelectric signals for long distances without any loss of signal strength. Second, they possess specific intercellular connections with other nerve cells and with innervated tissues such as muscles and glands. These connections determine the types of information a neuron can receive and the range of responses it can yield in return.

CYTOLOGY OF THE NERVE CELL

We do not need the high resolution of the electron microscope to identify the characteristic structural features of the nerve cell. The classic studies of Cajal (Santiago Ramón y Cajal to his friends) demonstrated that nerve cells are heterogeneous in both size and shape. An essential structural feature of the nervous system is that each specific region of the brain and each part of each nerve cell often have several synonymous names. So, for example, we find that the body of the nerve cell is also called the soma and the perikaryon—literally, the part that surrounds the nucleus. A fundamental scheme classifies nerve cells by the number of cytoplasmic processes they possess. In the simplest case, the perikaryon has one process, called an axon; the best examples of this cell type are the sensory neurons whose perikarya occur in groups in the sensory or dorsal root ganglia. In this case, the axon conducts the signal—which was generated by

the sensory receptor in the skin or other viscera—centrally through the dorsal root into the spinal cord or cranial nerve nuclei. At the next step of complexity we find neurons possessing two processes: the bipolar nerve cells. The sensory receptor nerve cells of the retina, the olfactory mucosa, and the auditory nerve are of this form, as is a class of small nerve cells of the brain known as granule cells.

All other nerve cells tend to fall into the class known as multipolar nerve cells. These cells possess only one axon or efferent-conducting process which may be short or long, branched or straight, and which may possess a recurrent or collateral branch that feeds back onto the same type of nerve cell from which the axon arises. Their main differences relate to the extent and size of the receptive field of the neuron, termed the dendrites or dendritic tree. In silver-stained preparations for the light microscope, the branches of the dendrites look like trees in wintertime, although the branches may be long and smooth, short and complex, or bearing short spines like a cactus. It is on these dendritic branches as well as on the cell body where the termination of axons from other neurons makes the specialized interneuronal communication point known as the synapse.

The Synapse

The characteristic specialized contact zone that has been presumptively identified as the site of functional interneuronal communication is the synapse. It contains special organelles. As the axon approaches the site of its termination, it exhibits structural features not found more proximally. Most striking is the occurrence of dilated regions of the axon (varicosities) within which are clustered large numbers of microvesicles (synaptic vesicles). These synaptic vesicles tend to be spherical in shape, with diameters varying between 400 and 1200 Å. Depending upon the type of fixation used, the shape and staining properties of the vesicles can be related to their neurotransmitter content. The nerve endings also exhibit mitochondria, but do not exhibit microtubules unless the varicosity is a “pre-terminal” region of an axon as it extends towards its terminal target. One or more of these varicosities may form a specialized contact

with one or more dendritic branches before the ultimate termination. Such endings are known as *en passant* terminals. In this sense, the term “nerve terminal” or “nerve ending” connotes a functional transmitting site rather than the end of the axon.

Electron micrographs of synaptic regions in the central nervous system reveal a specialized contact zone between the axonal nerve ending and the postsynaptic structure (Fig. 2-1). This specialized contact zone is composed of presumed proteinaceous material lining the intracellular portions of the pre- and postsynaptic membranes and filling the synaptic cleft between the apposed cell surfaces. Such types of specialized contacts are a general form of the specialized cell contacts seen between many types of cells derived from the embryonic ectoderm, of which the nerve cell is but one. However, the specialized contact between neurons is polarized; that is, the presynaptic terminal intracellular material is composed of interrupted presynaptic dense projections measuring about 500–700 Å in diameter and separated from each other by distances of 300–400 Å. This material may be present only to bind specific presynaptic nerve endings permanently to specific postsynaptic cell sites. Alternatively, the specialized contact zone could assist in the efficiency of transmission and could constitute one potential method for modulating the efficacy of synaptic transmission. All aspects of the release and reuptake of transmitter function quite well, however, in the peripheral nervous system with no apparent specializations. In some neurons, especially these single-process small granule cell types, the “dendrite” may also be structurally specialized to store and release transmitter.

Glia

A second element in the maintenance of the neuron’s integrity depends on a type of cell known as neuroglia. There are two main types of neuroglia. The first is called the fibrous astrocyte, a descriptive term based on its starlike shape when viewed in the light microscope and on the fibrous nature of its cytoplasmic organelles, which can be seen with both light and electron microscopy. The